University of Maryland Medicine, the joint enterprise of the University of Maryland School of Medicine, the University of Maryland Medical Center, and University of Maryland Medical System, today launched a landmark initiative called My Healthy Maryland Precision Medicine Research. The project aims to enroll 250,000 Maryland residents over the next decade who reflect the diversity of the state and want to play a pivotal role in helping researchers understand how genes and lifestyle affect an individual’s health.
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
Sirnaomics Ltd. (“Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead therapeutic candidate, STP705, for the treatment of skin cancer, in the May 2022 issue of the Journal of Drugs in Dermatology (the “JDD”). The study, titled “Safety and Efficacy of TGF-β1/COX-2 Silencing Therapeutic in Adults with Cutaneous Squamous Cell Carcinoma In Situ,” showed that STP705 was safe and well-tolerated in patients with Cutaneous Squamous Cell Carcinoma In Situ (isSCC).
With steadfast listening and support, well-structured corporate benefit plans, and broad flexibility, PQE maintains a continuous dialogue with its employees. As a result, PQE Group, among the leading international consulting firms in the pharma world, has achieved recognition in the United States by Great Place to Work®, the world authority on workplace culture. After analyzing the feedback of U.S. employees and after collecting HR policies, the organization declared that the PQE USA Affiliate is an excellent work environment “where employees believe in the people they work for, take pride in what they do, and are comfortable with the people they work with.”
Shimadzu Scientific Instruments (SSI) is pleased to announce the next phase in their planned expansion with the procurement of additional facilities at their headquarters in Columbia, Maryland. The purchase of a new two-story building has been finalized, bringing the campus to a total of three separate properties.
hortly after the news dropped, Nick Fullenkamp began scouring for space to accommodate his team’s future.
Avidea Technologies, a Baltimore-born developer of immunotherapies, had been acquired in December in a splashy $40 million deal by high-profile UK biopharma firm Vaccitech. The 14-employee startup, since folded in as Vaccitech’s North American subsidiary, would be doubling in size and needed a true home base after the five years it spent growing in Johns Hopkins Tech Ventures’s (JHTV) FastForward 1812 incubator in East Baltimore.
Fullenkamp’s search led him up and down I-95. Staying in Baltimore was on the table in at least one space, but ultimately, a larger build-out allowance in Montgomery County and a landlord experienced with managing lab spaces were too enticing to pass up. While the exact location remains publicly unannounced until a lease is signed, Vaccitech US is set to move in early next year.
Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion. This is the third Breakthrough Designation for Theradaptive in spinal fusion, along with transforaminal interbody and posterolateral fusion, allowing it to address over 90% of lumbar spinal fusion procedures.
Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds raised in the offering were $128.8 million, before deducting underwriting discounts and commissions and offering expenses, payable by Arcellx. All shares in the offering were offered by Arcellx.
Kemp Proteins, a leading CDMO specializing in the production and characterization of novel proteins, from mammalian, insect, and bacterial host cells, for the pharmaceutical, diagnostics, and research industries, announced today that it has secured financing from BroadOak Capital Partners, LLC (“BroadOak”). The transaction with BroadOak provides Kemp Proteins with capital to expand its bacteria expression and plasmid production services in Frederick, MD.
American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue the developments in monogenic disease and immuno-oncology.
Located in the northern part of Maryland along the I-270 Technology Corridor, Frederick County is home to more than 80 bioscience companies. With proximity to Fort Detrick, home to the Frederick National Laboratory for Cancer Research, the county boasts a powerful environment of life sciences intellectual prowess.